C. Yurdaydin Et Al. , "A phase 2 dose-optimization study of lonafarnib with ritonavir for the treatment of chronic delta hepatitis-analysis from the LOWR HDV-2 study using the robogene (R) real-time qPCR HDV RNA assay," 16th International Symposium on Viral Hepatitis and Liver Diseases (ISVHLD) , vol.25, Toronto, Canada, pp.10, 2018
Yurdaydin, C. Et Al. 2018. A phase 2 dose-optimization study of lonafarnib with ritonavir for the treatment of chronic delta hepatitis-analysis from the LOWR HDV-2 study using the robogene (R) real-time qPCR HDV RNA assay. 16th International Symposium on Viral Hepatitis and Liver Diseases (ISVHLD) , (Toronto, Canada), 10.
Yurdaydin, C., Idilman, R., Keskin, O., Kalkan, C., Karakaya, F. M., Caliskan, A., ... Yurdcu, E.(2018). A phase 2 dose-optimization study of lonafarnib with ritonavir for the treatment of chronic delta hepatitis-analysis from the LOWR HDV-2 study using the robogene (R) real-time qPCR HDV RNA assay . 16th International Symposium on Viral Hepatitis and Liver Diseases (ISVHLD) (pp.10). Toronto, Canada
Yurdaydin, C. Et Al. "A phase 2 dose-optimization study of lonafarnib with ritonavir for the treatment of chronic delta hepatitis-analysis from the LOWR HDV-2 study using the robogene (R) real-time qPCR HDV RNA assay," 16th International Symposium on Viral Hepatitis and Liver Diseases (ISVHLD), Toronto, Canada, 2018
Yurdaydin, C. Et Al. "A phase 2 dose-optimization study of lonafarnib with ritonavir for the treatment of chronic delta hepatitis-analysis from the LOWR HDV-2 study using the robogene (R) real-time qPCR HDV RNA assay." 16th International Symposium on Viral Hepatitis and Liver Diseases (ISVHLD) , Toronto, Canada, pp.10, 2018
Yurdaydin, C. Et Al. (2018) . "A phase 2 dose-optimization study of lonafarnib with ritonavir for the treatment of chronic delta hepatitis-analysis from the LOWR HDV-2 study using the robogene (R) real-time qPCR HDV RNA assay." 16th International Symposium on Viral Hepatitis and Liver Diseases (ISVHLD) , Toronto, Canada, p.10.
@conferencepaper{conferencepaper, author={C. Yurdaydin Et Al. }, title={A phase 2 dose-optimization study of lonafarnib with ritonavir for the treatment of chronic delta hepatitis-analysis from the LOWR HDV-2 study using the robogene (R) real-time qPCR HDV RNA assay}, congress name={16th International Symposium on Viral Hepatitis and Liver Diseases (ISVHLD)}, city={Toronto}, country={Canada}, year={2018}, pages={10} }